| Bioactivity | Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3]. |
| Invitro | Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2]. Western Blot Analysis[2] Cell Line: |
| In Vivo | Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD[3]. Animal Model: |
| Name | Naproxcinod |
| CAS | 163133-43-5 |
| Formula | C18H21NO6 |
| Molar Mass | 347.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5. [2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. [3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49. |
Naproxcinod
CAS: 163133-43-5 F: C18H21NO6 W: 347.36
Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Nap
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.